Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapagliflozin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Dapagliflozin. Displaying page 7 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2020-002263-54 Sponsor Protocol Number: D7551C00001 Start Date*: 2021-03-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease
    Medical condition: Proteinuric Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001702-33 Sponsor Protocol Number: CV181-369 Start Date*: 2016-01-07
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-admini...
    Medical condition: Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metformin
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10049746 Insulin-requiring type II diabetes mellitus LLT
    19.0 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002229-27 Sponsor Protocol Number: TACTIC-E Start Date*: 2020-06-09
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Experimental drugs and mechanisms
    Medical condition: SARS-Cov-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-012806-37 Sponsor Protocol Number: D1690C00010 Start Date*: 2009-10-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflo...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006324-20 Sponsor Protocol Number: MB102-129 Start Date*: 2012-11-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    15.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006323-37 Sponsor Protocol Number: CV181-168 Start Date*: 2012-10-17
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combinati...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002046-20 Sponsor Protocol Number: FIBHGM-ECNC001-2019 Start Date*: 2020-07-22
    Sponsor Name:Fundación para la Innovación en Biomedicina-FIBMED
    Full Title: Effects of SGLT2 inhibition on the mechanisms of cardiac damage in the diabetic patient with HFpEF.-CARDIA-STIFF.
    Medical condition: Patients with Diabetes mellitus type 2 and Heart Failure with preserved Ejection Fraction.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001046-17 Sponsor Protocol Number: SMART-2019 Start Date*: 2019-05-02
    Sponsor Name:Uppsala University
    Full Title: A multicentre, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascu...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004832-48 Sponsor Protocol Number: GN19CA407 Start Date*: 2020-12-17
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controll...
    Medical condition: Diuretic resistant heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    20.0 100000004849 10066159 Decompensated heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    20.0 10042613 - Surgical and medical procedures 10053073 Diuretic therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-006854-29 Sponsor Protocol Number: CLIgAN Start Date*: 2022-09-28
    Sponsor Name:Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
    Full Title: A multicentre, prospective, open-label, randomized CLinical study to evaluate the effect of personalized therapy on patients with Immunoglobulin A Nephropathy (CLIgAN)
    Medical condition: Idiopathic IgA nephropathy (IgAN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004614-35 Sponsor Protocol Number: ECO-02 Start Date*: 2021-11-23
    Sponsor Name:Ismail Gögenur
    Full Title: Treatment with SGLT-2 inhibitor for postoperative hyperglycemia in acute abdominal surgery – a randomized trial
    Medical condition: Postoperative (stress) hyperglycemia in patients with no known diabetes after acute abdominal surgery
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10042216 Stress induced hyperglycemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002963-40 Sponsor Protocol Number: IDAPADM1 Start Date*: 2015-10-26
    Sponsor Name:Dra Cristina Avendaño Sola
    Full Title: Impact of treatment with Dapagliflozin (SGLT2 inhibitor) in metabolic control and glycemic pattern in type 1 diabetic patients
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001454-33 Sponsor Protocol Number: DEXBASU Start Date*: 2017-08-07
    Sponsor Name:Dr. Albert Lecube Torello
    Full Title: A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surg...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003497-48 Sponsor Protocol Number: EMPATHY Start Date*: 2021-11-29
    Sponsor Name:Medical University of Warsaw
    Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004637-27 Sponsor Protocol Number: AZ-01_SGLT-2 Start Date*: 2016-01-21
    Sponsor Name:Medizinische Universität Graz
    Full Title: A randomized, double-blind, three arm, three treatment period, cross-over trial to investi-gate the effect of a SGLT-2 inhibitor, a DPP-4 inhibitor and a SGLT-2 inhibitor + DPP-4 inhibitor on gluca...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002813-33 Sponsor Protocol Number: ARMYDA-9DAPAtrial Start Date*: 2023-02-21
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
    Full Title: Early use of dapaglifozin in diabetic patients with acute myocardial infarction and reduced ejection fraction: the randomized ARMYDA-9 DAPA trial
    Medical condition: Patients with type 2 diabetes and ST-elevation myocardial infarction treated with primary primary percutaneous coronary intervention and reduced left ventricle ejection fraction.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064346 STEMI LLT
    20.0 100000004849 10011949 Decompensation cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002417-29 Sponsor Protocol Number: NN2211-4232 Start Date*: 2016-01-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-001661-21 Sponsor Protocol Number: WP3.protocol.v7 Start Date*: 2022-02-08
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000740-29 Sponsor Protocol Number: 270389-030122 Start Date*: 2022-04-12
    Sponsor Name:Department of Renal Medicine, Aarhus University Hospital
    Full Title: Sodium glucose cotransporter 2 inhibitors or Mineralocorticoid receptor antagonists for the treatment of Albuminuric Chronic Kidney Disease - A randomized controlled trial
    Medical condition: Chronic Kidney Disease with albuminuria
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-002453-25 Sponsor Protocol Number: MERCURI-2 Start Date*: 2023-03-07
    Sponsor Name:Amsterdam UMC
    Full Title: Preoperative sodium glucose cotransporter 2 inhibitors for prevention of postoperative acute kidney injury in cardiac surgery patients – a randomized, placebo-controlled, multi-centre, phase IV cli...
    Medical condition: Cardiac Surgery-Associated Acute Kidney Injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10080266 Stage 1 acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 23:50:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA